Anti-EGFR-hmLIGHT treatment induced complete tumor regression of small (7-days post s.c. injection) Ag104Ld-EGFR+ primary tumors as well as protected against re-challenge, but had little success as a monotherapy when the parental Ag104Ld tumor line was not over-expressing EGFR or tumors were older than 14 days (57). This evidence concerns the gene EGFR and neoplasm.